Article Details

Arcutis Biotherapeutics (NASDAQ:ARQT) Rating Increased to Overweight at Morgan Stanley

Retrieved on: 2021-05-27 11:03:45

Tags for this article:

Click the tags to see associated articles and topics

Arcutis Biotherapeutics (NASDAQ:ARQT) Rating Increased to Overweight at Morgan Stanley. View article details on hiswai:

Excerpt

The firm currently has a $52.00 price target on the stock. Morgan Stanley's target price suggests a potential upside of 102.18% from the company's ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up